The effect of liver ChREBP on aerobic exercise preventing HFD-induced NAFLD in C57BL/6 mice
TUN Hao, LIU Chang, GUAN You-Fei, WANG Chun-Gui, LI Sha
Chinese Journal of Clinical Anatomy ›› 2014, Vol. 32 ›› Issue (4) : 446-450.
The effect of liver ChREBP on aerobic exercise preventing HFD-induced NAFLD in C57BL/6 mice
Objective To investigate the effect of ChREBP and its downstream target genes on 12-week aerobic exercise prevention C57BL/6 mice with nonalcoholic fatty liver. Methods Forty-two male C57BL/6 mice were randomized into four groups (n=8~13): the normal diet sedentary group (ND) (n=8), the normal diet exercised group (ND-Ex), the high-fat diet sedentary group (HFD) and the high-fat diet exercised group (HFD-Ex). After the simultaneous starting of high-fat diet feeding, the mice were submitted to an aerobic swimming training protocol (60 minutes/day) five days per week, for 12 weeks. At the end of the experiment, mice liver, blood triglycerides and total cholesterol, fasting blood glucose, oral glucose tolerance were determined. The expression of ChREBP and its downstream target genes were measured by RT-PCR. The level of Akt phosphorylation in liver was measured by Western blot. Result Compared with group ND, group HFD had significantly higher body weight, impaired oral glucose tolerance, dyslipidemia, liver steatosis and NAFLD. The expression of ChREBP and its downstream target genes in group HFD were significantly increased, and the level of Akt phosphorylation in liver was decreased. Compared with group HFD, aerobic exercise reduced overweight and all the other worst findings, especially NAFLD in group HFD-Ex. The expression of ChREBP and its downstream target genes in group HFD-Ex were decreased, and the level of Akt phosphorylation in liver was increased. Conclusion Aerobic exercise has a preventive effect on high-fat diet-induced NAFLD, and this may be related to aerobic exercise inhibition of ChREBP and its downstream target genes expression.
Aerobic exercise / non-alcoholic fatty liver disease / ChREBP / FAS / SCD1
[1] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China
[J]. J Hepatol, 2009, 50(1): 204-210.
[2] Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment
[J]. Curr Diab Rep, 2008, 8(1): 25-30.
[3] Sourianarayanane A, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease
[J]. Minerva Gastroenterol Dietol, 2013,59(1): 69-87.
[4] American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults
[J]. Med Sci Sports Exerc, 2009, 41(3): 687-708.
[5] Li J, Chi Y, Wang C, et al. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway
[J]. Hepatology, 2011, 53(6):1906-1916.
[6] Yang J, Wang C, Li J, et al. PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells
[J]. FEBS Lett, 2009, 583(18): 3009-3015.
[7] Day CP. Pathogenesis of steatohepatitis
[J]. Best Pract Res Clin Gastroenterol, 2002,16(5): 663-678.
[8] van der Heijden GJ, kWang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents
[J]. Obesity (Silver Spring), 2010, 18(2): 384-390.
[9] Sullivan S,Kirk EP, Mittendorfer B, et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease
[J]. Hepatology, 2012, 55(6): 1738-1745.
[10]Iizuka K, Miller B, Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice
[J]. Am J Physiol Endocrinol Metab, 2006, 291(2): E358-364.
[11]Dentin R, Benhamed F, Hainault I, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice
[J]. Diabetes, 2006, 55(8): 2159-2170.
[12]Guinez, C., et al., O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver
[J]. Diabetes, 2011, 60(5):1399-1413.
/
| 〈 |
|
〉 |
